TARS

TARS EBITDA Growth

56.53%TTM

Period ending:

TARS TTM EBITDA YoY %%
TARS TTM EBITDA YoY %207.65%-1344.98%
2020-12-312026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

TARS ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 23 observations from Dec 31, 2020 to Jun 30, 2026.

Tarsus Pharmaceuticals Inc EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
56.5333%
57.3918%
47.4681%
42.651%
43.6685%
34.2048%
19.1692%
-21.8341%
-64.2122%
-130.0075%
-120.9119%
-68.8481%
-57.5091%
-41.544%
-343.0238%
-507.288%
-1,194.7234%
-213.8962%
49.9684%
38.6607%
39.1083%
-238.6247%
-1,032.9964%

Compare ebitda growth

All TARS financial metrics · TARS stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.